 |
 |
from: PR Newswire press release April 28, 2010, 7:00 a.m. EDT · Ceregene has Initiated a New Phase 1/2 Trial Of CERE-120 for Parkinson's Disease"SAN DIEGO, April 28, 2010 /PRNewswire via COMTEX/ -- Ceregene, Inc., a biopharmaceutical company, announced today that enrollment is proceeding in a new Phase 1/2 clinical study evaluating CERE-120, a gene therapy product which delivers the neurotrophic factor neurturin, to dying neurons in Parkinson's disease patients. This new clinical study follows a completed Phase 2 trial and builds on experience gained in that trial, by enhancing the dosing regimen and optimizing the duration of patient follow up. The new study was initiated in the fourth quarter of 2009 and is proceeding as planned. The ongoing Phase 1/2 trial will enroll six patients with advanced Parkinson's disease. The first four patients have been treated safely and two additional patients will be treated over the next two months. This Phase 1 open label portion of the trial is being conducted by Drs. Mark Stacy and Dennis Turner at Duke University School of Medicine, Drs. Michele Tagliati and Ron Alterman at Mount Sinai Medical Center, New York, and Drs. Stewart Factor and Nicholas Boulis at Emory University Hospital. Ceregene expects to initiate the next phase of this trial (a sham-surgery-controlled, double-blind Phase 2 portion) beginning during the third quarter of this year. The Phase 2 portion will include 10 leading US neurological medical centers. " full article at:http://www.marketwatch.com/story/ceregene-has-initiated-a-new-phase-12-trial-of-cere-120-for-parkinsons-disease-2010-04-28?reflink=MW_news_stmp __._,_.___ __,_._,___ ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn